Azurity Loses Hypertension Drug Patent Trial Against Alkem
A federal judge sitting in Delaware ruled Friday that several claims of two patents on Azurity Pharmaceuticals Inc.'s hypertension drug Epaned are invalid, handing a win to Alkem Laboratories Ltd., which...To view the full article, register now.
Already a subscriber? Click here to view full article